Evidence map›Paper›PMID 42016235›Full record

ReviewFood science & nutrition2026

Obesity and Natural Products: Mechanisms, Therapeutic Potential, and Future Directions.

Ohoud M Marie, Abdelghafar Abu-Elsaoud

Abstract readReview
In one paragraph

Review in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ohoud M MarieChemistry Department, Faculty of Science Suez Canal University Ismailia Egypt.ORCID https://orcid.org/0000-0003-2846-8476
Abdelghafar Abu-ElsaoudDepartment of Biology, College of Science Imam Mohammad Ibn Saud Islamic University (IMSIU) Riyadh Saudi Arabia.ORCID https://orcid.org/0000-0002-6269-3418

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity represents a major global public health challenge, currently affecting over 890 million adults worldwide and substantially increasing the risk of type 2 diabetes, cardiovascular diseases, and metabolic syndrome. Although several pharmacological agents are available for obesity management, their clinical use is often limited by adverse effects, high costs, and suboptimal long-term efficacy. These limitations have driven growing interest in natural products as complementary or alternative therapeutic options. Bioactive compounds derived from medicinal plants, fruits, and vegetables, such as polyphenols, flavonoids, alkaloids, terpenoids, saponins, and carotenoids, have shown promising anti-obesity effects through multi-targeted mechanisms. This narrative review summarizes current in vitro, preclinical, and clinical evidence on the role of natural products in obesity management, with particular emphasis on their ability to modulate lipid metabolism, inhibit adipogenesis, enhance energy expenditure, regulate appetite-related pathways, influence gut microbiota, and attenuate oxidative stress and inflammation. Compounds including epigallocatechin-3-gallate, curcumin, resveratrol, capsaicin, and berberine have demonstrated notable efficacy in experimental models, with increasing clinical data supporting their therapeutic potential. Nonetheless, challenges related to standardization, bioavailability, quality control, and regulatory approval remain major barriers to clinical translation. Addressing these issues is essential for the rational integration of natural products into evidence-based obesity management strategies.

Indexed as

adipogenesisantioxidantsfunctional foodsinsulin resistancemetabolic syndromenatural productsobesityphytochemicals

Identifiers

PMID42016235
PMCPMC13093847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.